Alkermes Plc Webinar on ALKS 3831 ENLIGHTEN-2 Data Transcript
Greetings, and welcome to the Alkermes Conference Call to discuss ALKS 3831 ENLIGHTEN-2 data. (Operator Instructions) Please note that this conference is being recorded. I'll now turn the call over to Sandy Coombs, Vice President of Investor Relations. Sandy, you may begin.
Thank you, and welcome to the Alkermes plc conference call to discuss ALKS 3831, our investigational agent for the treatment of schizophrenia. Last fall, we announced top line data from ENLIGHTEN-2, and today, we're presenting detailed results of the study from the Congress of the Schizophrenia International Research Society in Orlando. With me today are Richard Pops, our CEO; Craig Hopkinson, our Chief Medical Officer and Senior Vice President of Medicines Development and Medical Affairs; and special guest, Dr. René Kahn. Dr. Kahn is the Chair of the Department of Psychiatry at the Icahn School of Medicine at Mount Sinai.
Please note that during today's call, we will reference slides that are available on the webcast. A PDF of the slides
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |